Hemab Therapeutics Holdings (COAG) is trading down at $30.32 (-2.54%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
| Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|
| Income statement | ||||
| Operating income | −$16.6M | −$16.1M | −$23.6M | −$26.1M |
| Net income | −$15.3M | −$12.2M | −$22.7M | −$24.1M |
| EPS (diluted) | −$16.18 | −$12.91 | −$23.98 | −$0.80 |
| Balance sheet | ||||
| Cash and equivalents | — | — | $49.9M | $237.4M |
| Total assets | — | — | $175.3M | $467.8M |
| Total liabilities | — | — | $13.7M | $13.5M |
| Shareholders' equity | −$129.1M | −$141.5M | −$198.6M | $454.3M |
| Cash flow | ||||
| Operating cash flow | −$13.0M | −$15.3M | −$21.6M | −$22.6M |
| Capital expenditure | $16.0K | $0 | $112.0K | $23.0K |
| Free cash flow | −$13.0M | −$15.3M | −$21.7M | −$22.7M |
From Hemab Therapeutics Holdings's 10-Q filings with the SEC. Each period shows the latest figure the company has reported for it, including restatements. Filings on SEC EDGAR →
No recent news mentioning Hemab Therapeutics Holdings in our feed yet.